InvestorsHub Logo
Followers 8
Posts 3255
Boards Moderated 0
Alias Born 12/29/2004

Re: longmike2 post# 1005

Monday, 09/11/2017 8:56:08 AM

Monday, September 11, 2017 8:56:08 AM

Post# of 1346


MORE GOOD NEWS !!!!


September 11, 2017, 6:50 am EDT

AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces the first-in-human intravenous administration of AmpliPhi’s drug candidate AB-SA01. AmpliPhi supplied AB-SA01 to a major hospital in Australia for a patient suffering from a life-threatening Staphylococcus aureus (S. aureus) infection of the heart (endocarditis). AB-SA01 was administered intravenously to the patient over two weeks and was well tolerated.

Read Full Release

--
If you no longer wish to receive alerts from Official Investor News from AmpliPhi Biosciences, update your alert settings here: http://investor.ampliphibio.com/alerts

________________________________________
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ARMP News